NCT04019717View on ClinicalTrials.gov

Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 20, 2019

Primary Completion Date

January 29, 2020

Study Completion Date

March 23, 2020

Conditions
Hepatitis CHepatitis C, ChronicChronic Hepatitis CHepatitis C Virus InfectionHCV Infection
Interventions
DRUG

AT-527

Nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase

DRUG

Daclatasvir

Inhibitor of HCV nonstructural protein 5A (NS5A)

Trial Locations (3)

Unknown

Clinical Trial Site, Antwerp

Clinical Trial Site, Phoenix

Clinical Trial Site, Chisinau

Sponsors
All Listed Sponsors
lead

Atea Pharmaceuticals, Inc.

INDUSTRY